There are several therapeutic approaches now approved or in clinical trials, including gene therapy or antisense oligonucleotides (ASO) for exon skipping (to restore an internally truncated dystrophin form, converting DMD to the milder Becker muscular dystrophy, BMD) [5]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.